Clinical-Grade Wearables: De-Risking Cardiac AI for VCs
The promise of value-based care (VBC) hinges on demonstrable outcomes and verifiable cost reductions. For investors eyeing the burgeoning cardiac AI market, distinguishing between platforms…
AI in VBC: Why Long-Term Outcomes Drive Contract Success
The promise of AI in healthcare is vast, yet its true impact on value-based care (VBC) hinges not on ephemeral pilot results, but on demonstrable,…
Cardiac AI: The Billion Dollar VBC Opportunity Investors Can’t Miss
The promise of artificial intelligence in healthcare is vast, yet for health plan executives and investors, the critical question remains: which AI applications deliver tangible,…
Stop the ROI Mirage: Demand Real AI Health Outcomes Now
The promise of artificial intelligence in healthcare is vast, offering pathways to improved outcomes and significant cost reductions. However, for employers and health plan executives…
VBC AI: Peer-Reviewed Data Unlocks Billions in Health Tech
The promise of artificial intelligence in healthcare is vast, yet its integration into value-based care (VBC) models hinges on a singular, non-negotiable requirement: robust, peer-reviewed…
AI Health Outcomes: Self-Insured Employers’ VBC Negotiation Edge
Self-insured employers and their human resources leaders face a critical juncture in managing healthcare costs: the promise of artificial intelligence (AI) to deliver efficiencies and…
Pear’s Implosion: The Billion Dollar DTx Reimbursement Failure
The recent implosion of Pear Therapeutics, once a darling of the digital therapeutics (DTx) space, serves as a stark, cautionary tale for investors and health…
Population AI vs. Wellness Apps: The VBC Eligibility Divide
The burgeoning landscape of AI in healthcare presents a critical divide for health plans and employers: distinguishing between solutions genuinely poised for value-based care (VBC)…
Cardiac AI: The Billion-Dollar VBC Prevention Play
The promise of artificial intelligence in healthcare often conjures visions of advanced diagnostics and personalized treatment plans. Yet, for health plan executives and investors navigating…
AI for Investors: Measuring Cost Avoidance in High-Cost Patients
The stark reality of healthcare economics is that a mere 5% of patients drive 50% of total spending. For investors, this concentration of cost represents…